Ausgabe 4/2021
Inhalt (31 Artikel)
Identify potential miRNA-mRNA regulatory networks contributing to high-risk neuroblastoma
Feng-Ling Shao, Qing-qing Liu, Shan Wang
A novel ligand of the translationally controlled tumor protein (TCTP) identified by virtual drug screening for cancer differentiation therapy
Nicolas Fischer, Ean-Jeong Seo, Sara Abdelfatah, Edmond Fleischer, Anette Klinger, Thomas Efferth
Screening and identification of potential biomarkers and therapeutic drugs in melanoma via integrated bioinformatics analysis
Bo Chen, Donghong Sun, Xiuni Qin, Xing-Hua Gao
Autophagy promotes oncolysis of an adenovirus expressing apoptin in human bladder cancer models
Chao Shang, Yi-Long Zhu, Yi-Quan Li, Gao-Jie Song, Chen-Chen Ge, Jing Lu, Zhi-Ru Xiu, Wen-Jie Li, Shan-Zhi Li, Jia-Nan Cong, Zi-Rui Liu, Xiao Li, Li-Li Sun, Ning-Yi Jin
Histone deacetylase inhibitor chidamide regulates the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL
Linlin Zhao, Chengfang Lv, Lili Sun, Qi Li, Yuhuang Wang, Min Wu, Yuying Wang, Zhibo Guo, Sicheng Bian, Desheng Kong, Leilei Lin, Yu Wang, Jin Zhou, Yinghua Li
A novel methylated analogue of L-Mimosine exerts its therapeutic potency through ROS production and ceramide-induced apoptosis in malignant melanoma
Sotiris Kyriakou, William Cheung, Theodora Mantso, Melina Mitsiogianni, Ioannis Anestopoulos, Stephany Veuger, Dimitris T. Trafalis, Rodrigo Franco, Aglaia Pappa, David Tetard, Mihalis I. Panayiotidis
Rapamycin synergizes the cytotoxic effects of MEK inhibitor binimetinib and overcomes acquired resistance to therapy in melanoma cell lines in vitro
Oxana O. Ryabaya, Ivan S. Abramov, Dmitry A. Khochenkov, Roman Akasov, Nataly V. Sholina, Anastasia A. Prokofieva
Aurora kinase A inhibitor, LY3295668 erbumine: a phase 1 monotherapy safety study in patients with locally advanced or metastatic solid tumors
Quincy Siu-chung Chu, Nathaniel Bouganim, Caroline Fortier, Sara Zaknoen, John R. Stille, Jill D. Kremer, Eunice Yuen, Yu-Hua Hui, Amparo de la Peña, Andrew Lithio, Patricia S. Smith, Gerald Batist
Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers
Yun-ting Zhu, Yi-fan Zhang, Jin-fang Jiang, Yong Yang, Li-xia Guo, Jing-jing Bao, Da-fang Zhong
A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy
Toni K. Choueiri, Michael B. Atkins, Tracy L. Rose, Robert S. Alter, Yawen Ju, Katie Niland, Yan Wang, Robert Arbeit, Sudha Parasuraman, Lu Gan, David F. McDermott
A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma
Monica Balzarotti, Massimo Magagnoli, Miguel Ángel Canales, Paolo Corradini, Carlos Grande, Juan-Manuel Sancho, Francesco Zaja, Anne-Marie Quinson, Valérie Belsack, Daniela Maier, Carmelo Carlo-Stella
A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors
Noboru Yamamoto, Toshio Shimizu, Kan Yonemori, Shigehisa Kitano, Shunsuke Kondo, Satoru Iwasa, Takafumi Koyama, Kazuki Sudo, Jun Sato, Kenji Tamura, Junichi Tomomatsu, Makiko Ono, Naoki Fukuda, Shunji Takahashi
First‐in‐human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies
Sarina A. Piha-Paul, Kyaw Z. Thein, Paul De Souza, Richard Kefford, Tara Gangadhar, Christopher Smith, Shelly Schuster, William C. Zamboni, Claire E. Dees, Ben Markman
LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial
Afshin Dowlati, R. Donald Harvey, Richard D. Carvajal, Omid Hamid, Samuel J. Klempner, John Sae Wook Kauh, Daniel A. Peterson, Danni Yu, Sonya C. Chapman, Anna M. Szpurka, Michelle Carlsen, Tonya Quinlan, Robert Wesolowski
Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance)
Nguyen H Tran, Nathan R Foster, Amit Mahipal, Thomas Byrne, Joleen Hubbard, Alvin Silva, Kabir Mody, Steven Alberts, Mitesh J. Borad
Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma
Marjorie G. Zauderer, Evan W. Alley, Johanna Bendell, Enrica Capelletto, Todd M. Bauer, Sophie Callies, Anna M. Szpurka, Suhyun Kang, Melinda D. Willard, Volker Wacheck, Anna M. Varghese
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors
Analia Azaro, Christophe Massard, William D. Tap, Philippe A. Cassier, Jaime Merchan, Antoine Italiano, Bailey Anderson, Eunice Yuen, Danni Yu, Gerard Oakley III, Karim A. Benhadji, Shubham Pant
A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
Alexey V. Danilov, Stephen E. Spurgeon, Tanya Siddiqi, Anne-Marie Quinson, Daniela Maier, Dionne Smith, Jennifer R. Brown
Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab‐paclitaxel for non‐squamous non‐small cell lung cancer with malignant pleural effusion
Motohiro Tamiya, Akihiro Tamiya, Hidekazu Suzuki, Yoshihiko Taniguchi, Kanako Katayama, Shojiro Minomo, Keiko Nakao, Naoko Takeuchi, Yoshinobu Matsuda, Yujiro Naito, Takayuki Shiroyama, Norio Okamoto, Kyoichi Okishio, Toru Kumagai, Shinji Atagi, Fumio Imamura, Tomonori Hirashima
Effects of glutamine for prevention of radiation-induced esophagitis: a double-blind placebo-controlled trial
Anas Alshawa, Alexandra Perez Cadena, Bettzy Stephen, Akhila Reddy, Tito R. Mendoza, Lacey McQuinn, Kristie Lawhorn, Abdulrazzak Zarifa, Alexander Maximilian Bernhardt, Senait Fessaheye, Carla L. Warneke, Joe Y. Chang, Aung Naing
System Xc−: a key regulatory target of ferroptosis in cancer
Man-ru Liu, Wen-tao Zhu, Dong-sheng Pei
Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors
Antian Gao, Xiao Pan, Xudong Yang, Zitong Lin
AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis
Jorge Antonio Elias Godoy Carlos, Keli Lima, Leticia Veras Costa-Lotufo, Andrei Leitão, João Agostinho Machado-Neto
Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy
Norikazu Matsuo, Koichi Azuma, Takashi Kojima, Hidenobu Ishii, Takaaki Tokito, Kazuhiko Yamada, Tomoaki Hoshino
Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy
Francesco Pasqualetti, Alessandra Gonnelli, Paola Orlandi, Eleonora Palladino, Noemi Giannini, Giovanni Gadducci, Roberto Mattioni, Sabrina Montrone, Elisa Calistri, Chiara Maria Mazzanti, Sara Franceschi, Valerio Ortenzi, Cristian Scatena, Katia Zavaglia, Giuseppe Nicolo Fanelli, Riccardo Morganti, Orazio Santonocito, Guido Bocci, Giuseppe Antonio Naccarato, Fabiola Paiar
Correction to: Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy
Francesco Pasqualetti, Alessandra Gonnelli, Paola Orlandi, Eleonora Palladino, Noemi Giannini, Giovanni Gadducci, Roberto Mattioni, Sabrina Montrone, Elisa Calistri, Chiara Maria Mazzanti, Sara Franceschi, Valerio Ortenzi, Cristian Scatena, Katia Zavaglia, Giuseppe Nicolo Fanelli, Riccardo Morganti, Orazio Santonocito, Guido Bocci, Antonio Giuseppe Naccarato, Fabiola Paiar
Pharmaceutical good manufacturing practice: Leuplin® production in Japan identifies major international shortcomings
Masahiro Wada, Akihiko Ozaki, Takashi Miyachi, Tetsuya Tanimoto, Andy Crump
Dissociated response and clinical benefit in patients treated with nivolumab monotherapy
Yuki Sato, Takeshi Morimoto, Shigeo Hara, Kazuma Nagata, Kazutaka Hosoya, Atsushi Nakagawa, Ryo Tachikawa, Keisuke Tomii
Discovery of an orally active antitumor agent that induces apoptosis and suppresses EMT through heat shock protein 90 inhibition
Yuqiang Hu, Ming Hao, Chang Zhong, Jun An, Yongsheng Zhang, Zuobin Zhu, Bing Liu, Liangjun Cheng
Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients
Julian Taugner, Lukas Käsmann, Chukwuka Eze, Alexander Rühle, Amanda Tufman, Niels Reinmuth, Thomas Duell, Claus Belka, Farkhad Manapov
Significant benefit of everolimus in a patient with urothelial bladder cancer harboring a rare M1043I mutation of PIK3CA
Shouhua Pan, Si Li, Mingzhe Xiao, Dongsheng Chen, Junlong Li